The estimated Net Worth of David R Walt is at least $122 million dollars as of 10 August 2022. David Walt owns over 150,000 units of Quanterix Corp stock worth over $17,275,936 and over the last 21 years he sold QTRX stock worth over $104,381,725. In addition, he makes $133,503 as Independent Director at Quanterix Corp.
David has made over 328 trades of the Quanterix Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 150,000 units of QTRX stock worth $1,293,000 on 10 August 2022.
The largest trade he's ever made was buying 1,000,000 units of Quanterix Corp stock on 2 August 2019 worth over $2,000,000. On average, David trades about 8,155 units every 17 days since 2004. As of 10 August 2022 he still owns at least 1,431,312 units of Quanterix Corp stock.
You can see the complete history of David Walt stock trades at the bottom of the page.
Dr. David R. Walt Ph.D. serves as Independent Director of the Company. Since 2017, Dr. Walt has served as Hansjörg Wyss Professor of Biologically Inspired Engineering and Professor of Pathology at Harvard Medical School in the Department of Pathology at the Brigham and Women's Hospital and as a core faculty member of the Wyss Institute for Biologically Inspired Engineering. He is also a Howard Hughes Medical Institute Professor. He previously served as University Professor, Professor of Chemistry, Professor of Biomedical Engineering, Professor of Genetics, Professor of Neuroscience, Professor of Cell and Molecular Biology, and Professor of Oral Medicine at Tufts University, from 1981-2017. Dr. Walt was also the founding scientist of Illumina, Inc. and served as a member of its board of directors from 1998-2016. He served on the board of directors of Cerulean Pharma Inc. (which was acquired by Daré Bioscience, Inc.) from August 2016 to July 2017. Dr. Walt was also a founder and currently serves as a member of the board of directors of Ultivue, Inc., Arbor Biotechnologies, Inc., Sherlock Biosciences, Inc., and Vizgen Biosciences and serves as a member of the board of directors of Exicure, Inc. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical sensors, microwell arrays and single molecule detection. He is a member of the U.S. National Academy of Engineering, U.S. National Academy of Medicine, American Academy of Arts and Sciences, a fellow of the American Institute for Medical and Biological Engineering, a fellow of the National Academy of Inventors, and a fellow of the American Association for the Advancement of Science. Dr. Walt has a B.S. in Chemistry from the University of Michigan and a Ph.D. in Chemical Biology from Stony Brook University.
As the Independent Director of Quanterix Corp, the total compensation of David Walt at Quanterix Corp is $133,503. There are 12 executives at Quanterix Corp getting paid more, with E. Kevin Hrusovsky having the highest compensation of $3,631,000.
David Walt is 67, he's been the Independent Director of Quanterix Corp since 2007. There are 1 older and 19 younger executives at Quanterix Corp. The oldest executive at Quanterix Corp is Dr. David R. Walt Ph.D., 68, who is the Co-Founder, Chairman of Scientific Advisory Board & Independent Director.
David's mailing address filed with the SEC is C/O QUANTERIX CORPORATION,, 900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821.
Over the last 7 years, insiders at Quanterix Corp have traded over $25,118,881 worth of Quanterix Corp stock and bought 1,481,095 units worth $18,701,541 . The most active insiders traders include David R Walt, Paul M Meister et Keith Crandell. On average, Quanterix Corp executives and independent directors trade stock every 7 days with the average trade being worth of $100,483. The most recent stock trade was executed by Masoud Toloue on 13 August 2024, trading 19,000 units of QTRX stock currently worth $207,100.
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
Quanterix Corp executives and other stock owners filed with the SEC include: